Alzheon is an American clinical-stage biopharmaceutical company based in Framingham, Massachusetts.[1] The company is developing medicines for patients with Alzheimer's disease and other neurological and psychiatric disorders.[2]
Alzheon was founded in July 2013 by Martin Tolar, MD, PhD, a veteran of Alzheimer's drug programs,[2] who serves as president and CEO of the organization.[3] Alzheon completed a $10 million Series A round of financing in April 2015[4][5]
In August 2018, Alzheon appointed former IVAX President Neil Flanzraich, JD, as Vice Chairman of Board of Directors.[8][9]
In August 2020, Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging, part of the National Institutes of Health. The grant is to support the Phase 3 clinical trial of ALZ-801 that began in May 2021[10][11]
Alzheon's leading candidate, valiltramiprosate (ALZ-801), is an oral prodrug of the active agent tramiprosate[12] that targets neurotoxic soluble amyloid oligomers,[13][14][15] and received Fast Track designation from the FDA in 2017.[10]
ALZ-801 oral tablet is being evaluated in Phase 2 biomarker study in early Alzheimer's disease patients with homozygous and heterozygous APOE4 genotype.[14]
ALZ-801 is also in Phase 3 clinical development for high-risk homozygous APOE4/4 patients with early Alzheimer's Disease.[10] Patients with two alleles of APOE4 have up to 20 times the risk of developing Alzheimer's disease.[16][17][18]
Alzheon completed a $50 million Series D in April 2022 and will use the funds to complete ALZ-801 clinical trials.[19]
